Effects of DKK1 overexpression on bone metastasis of SBC-3 cells

HAILIN PANG1*, NINGQIANG MA1*, WEIWEI SHEN1, QIANG ZHAO2, JIANLIN WANG3, LIAN DUAN1, WENJUAN CHEN1, NING ZHANG1, ZHENGEWEI ZHAO6, LILI LIU1 and HELONG ZHANG1

1Department of Oncology, Tangdu Hospital, The Fourth Military Medical University, Xi’an, Shaanxi 710038; 2Department of Oncology, The Third Hospital of PLA, Baoji, Shaanxi 721004; 3Department of Hepatobiliary Surgery, Xijing Hospital, The Fourth Military Medical University, Xi’an, Shaanxi 710032; 4Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi’an, Shaanxi 710038, P.R. China

Received April 16, 2017; Accepted January 19, 2018

DOI: 10.3892/ol.2018.8160

Abstract. Among all malignancies, lung cancer is the leading cause of cancer-related deaths in China. Bone metastasis is one of the most common complications and one of the most important factors affecting the prognosis of lung cancer patients, which resulting in very poor therapeutic effects. Previously, we have demonstrated that the expression levels of Dickkopf1 (DKK1), a protein involved in cell regulation and proliferation, was dramatically higher in cells that have a tendency to metastasize and invade the bone tissue (SBC-5 cells) compared with cells that do not (SBC-3 cells). Downregulation of DKK1 in SBC-5 cells inhibited cell malignancy in vitro, and the formation of bone metastasis in vivo. However, whether upregulating DKK1 would be sufficient to induce aggressive tumor behavior (proliferation, migration, invasion and metastasis) in SBC-3 cells remained to be investigated. The present study aimed to examine the role of DKK1 in SBC-3 cells, as well as to investigate the SBC-3 ability to metastasize and invade the bone tissue. The results demonstrated that upregulation of DKK1 in SBC-3 cells enhanced cell proliferation, colony formation, cell migration and invasion in vitro, as well as bone metastasis in vivo. These results indicate that DKK1 may be an important regulator in the development of small cell lung cancer (SCLC), and targeting DKK1 may be an effective method for preventing and/or treating skeletal metastases in SCLC cases.

Introduction

Lung cancer is the most common cancer in the world, in terms of both morbidity (1.8 million cases, 12.9% of total) and mortality (1.6 million deaths, 19.4% of total) (1). Bone is one of the most common sites of metastasis in patients with lung cancer, which is often accompanied by skeletal-related events which significantly reduce the quality of life in patients, including bone pain, hypercalcemia, pathological fractures, spinal cord compression and bone marrow infiltration (2-4). Consequently, effective targeted therapies for bone metastasis in lung cancer are urgently needed. However, the mechanisms underlying the development of bone metastasis are not well understood.

Dickkopf1 (DKK1) is known as a negative regulator of the Wnt signaling pathway (5), which regulates cell fate and proliferation. Dysregulation of this pathway has been reported in many developmental defects and cancer (6). Several studies suggest that DKK1 has a role in malignant bone metastasis, such as in breast cancer (6) and prostate cancer (7,8). Previously, a study from our group has demonstrated that the expression levels of DKK1 were significantly higher in SBC-5 cells compared with SBC-3 cells. SBC-5 cells have a greater propensity to metastasize to bone. In addition, downregulation of DKK1 in SBC-5 cells inhibited cell proliferation, colony formation, migration and invasion in vitro and bone metastasis in vivo; nevertheless, it also promoted cell apoptosis (9). However, it remained unclear whether upregulating DKK1 in SBC-3 cells could endow them with more aggressive properties, or even reverse their inability to form metastases in the bone. In the present study, DKK1 was overexpressed in SBC-3 cells and consequently its effects were examined in cell proliferation, colony formation, cell migration in vitro, and tumorigenic ability in NOD-SCID mice. The results further confirmed that DKK1, a critical tumor promoter, was associated with skeleton metastasis of SCLC. These data suggested that DKK1 may provide a potential novel strategy for therapeutic intervention in SCLC patients with bone metastases.

Materials and methods

Cell culture. SBC-5 and SBC-3 cells were a kind gift from Professors Sone and Yano (Tokushima University, Tokushima, Japan). Cells were cultured in RPMI1640 medium (Gibco; Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Biochrom GmbH, Berlin, Germany), 100 U/ml streptomycin and 100 U/ml penicillin at 37°C with 5% CO₂.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was isolated from cells using TRIzol reagent (Thermo Fisher Scientific, Inc.) following the manufacturer's instructions. Consequently, RNA (500 ng) was reverse-transcribed into cDNA by QuantiNova™ Reverse Transcription kit (QIAGEN GmbH, Hilden, Germany). qPCR was preformed using SYBR Premix Ex Taq™ II (TakaraBio, Inc., Otsu, Japan), the thermocycling conditions were denatured at 95°C for 30 sec, followed by 40 cycles at 95°C for 5 sec and 60°C for 30 sec, real-time fluorescence signals were detected, and gene expression was quantified using 2-ΔΔCq method (10). The primer sequences are listed in Table I.

Western blot analysis. The protein of cells was extracted by RIPA buffer (Beyotime Biotechnology, Shanghai, China), after quantification with BCA kit (Pierce, Thermo Fisher Scientific, Inc.), 20 µg of protein was subjected to 10% SDS-PAGE and transferred to nitrocellulose membranes. The members were then blocked in 5% fat-free milk for 1 h at room temperature and incubated overnight at 4°C with primary antibodies against DKK1 (1:15,000; BS7731; Bioworld Technology, St. Louis Park, MN, USA) or β-actin (1:10,000; 051M4892; Sigma-Aldrich, Merck KGaA, Darmstadt, Germany). Next, peroxidase-conjugated goat anti-rabbit IgG (1:5,000; ZB-2301; Zhongshan, Beijing, China) or peroxidase-conjugated goat anti-mouse IgG (1:5,000; ZB-2305; Zhongshan, Beijing, China) were incubated for 1 h at room temperature. Finally, the target proteins were visualized by chemiluminescence (Pierce, Thermo Fisher Scientific, Inc.).

Cells stable transfection. DKK1-overexpressing plasmids were obtained from Bioworld Technology, Inc. and 1.2 µg plasmids were transfected into SBC-3 cells in 6-well plates with Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. A total of 48 h after transfection, cells were selected with G418 sulfate (600 µg/ml). One month later, G418-resistant colonies, stably overexpressing DKK1 (termed SBC-3-DKK1 cells), were harvested and consequently subcultured in medium containing 200 µg/ml of G418. Parental SBC-3 cells were used as the control.

MTT assay. Cells in the logarithmic growth phase were harvested and plated in 96-well plates (2,000 cells/well), and cell growth was analyzed for the next days. Briefly, cells were incubated with MTT solution (5 mg/ml, 20 µl/well) at 37°C for 3 h. Then, the medium was removed and 150 µl DMSO was added to dissolve the formazane. The absorbance value was detected at 490 nm using a microplate reader. The assay was performed in triplicate.

Colony formation assay. Cells in the logarithmic growth phase were harvested and plated in 6-well plates (200 cells/well). Two weeks post-seeding, the cells were stained with 0.25% crystal violet and the number of colonies was counted manually. The assay was performed in triplicate.

Conditioned medium collection. SBC-5 cells were seeded in 6-well plate (1x10⁵ cells/well). At 24 h post-seeding, the cells were washed twice with PBS, mixed with serum-free medium, and then incubated for an additional 24 h. Then the conditioned medium (CM) was collected and stored at -80°C for further use.

Cell migration and invasion assay. The invading potential of the cells was investigated using 8-µm pore size transwell inserts (Corning Incorporated, Corning, NY, USA). Briefly, cells were first suspended in serum-free RPMI-1640 and then seeded in triplicates in the upper chamber of the transwells, which was pre-coated with 70 µl Matrigel (1:8 dilution; Corning Incorporated). A total of 500 µl of RPMI-1640 with 10% FBS was then added into the bottom chamber to serve as a chemoattractant. To examine the function of DKK1, anti-human DKK1-neutralizing antibody (10 µg/ml; R&D Systems, Inc., Minneapolis, MN, USA), recombinant human DKK1 (16 µg/ml; PeproTech, NJ, USA), or conditioned medium (CM) were also added to the bottom chambers. Following 24 h of incubation, cells that invaded to the lower chamber were fixed in 95% ethyl alcohol and then stained with 0.5% crystal violet. Finally, the number of invasive cells was counted in five random fields of each sample and the average was determined.

For migration assays, the same protocol was followed, with the only difference being that the inserts were not coated with Matrigel.

In vivo metastasis experiment. A total of 10 female NOD-SCID mice, 4 weeks old, weighing 20-25 g, were obtained from Beijing HFK Bioscience Co. (Beijing, China). Animals were divided into two groups of 5 mice each. SBC-3 cells and SBC-3-DKK1 cells were harvested, resuspended with PBS in a concentration of 5x10⁶ cells/ml and then injected by tail vein in the mice (200 µl). The mice were kept under germ-free conditions (temperature, 22°C; ventilation rate, 15/h, light/dark cycle, 12/12 h; food was sterilized with Cobalt-60 irradiation and water was autoclaved, and access to the food was ad libitum). Five weeks post-injection, mice were anesthetized and the

Table I. Primers used in quantitative polymerase chain reaction analysis.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward primer (5'-3')</th>
<th>Reverse primer (5'-3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>DKK1</td>
<td>TAGATGTCATAGAATGCAAGGATCTC</td>
<td>CAAAACATATCACAGCTAAAGGG</td>
</tr>
<tr>
<td>β-actin</td>
<td>TGGCACCCAGCACAATGAA</td>
<td>CTAAGTCATAGTCGGCCTAGAAGCA</td>
</tr>
<tr>
<td>DKK1, Dickkopf1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
bone metastases were investigated using an X-ray device. The imaging data of the osteolytic bone metastases were independently evaluated by two experienced investigators.

All animal studies (including the mice euthanasia procedure) were done in compliance with the regulations and guidelines of The Fourth Military Medical University Institutional Animal Care and conducted according to the AAALAC and the IACUC guidelines. The present study was approved by the Animal Experimental Ethical Inspection Committee of The Fourth Military Medical University Laboratory Animal Center (Xi'an, China).

**Statistical analysis.** One-way analysis of variance was used to analyze the statistical differences in cell migration and invasion assays. The other data was analyzed by t-test. Statistical tests were performed with GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA). *P*<0.05 was considered to indicate a statistically significant difference.

**Results**

*Expression levels of DKK1 were increased in transfected cells.* Transfection efficacy of DKK1 in SBC-3 cells was analyzed by RT-qPCR and western blotting. Briefly, DKK1 mRNA (Fig. 1A) and protein (Fig. 1B) expression levels in SBC-3-DKK1 cells were both stably increased compared with parental SBC-3 cells.

*Overexpression of DKK1 increases the proliferation ability of SBC-3 cells.* The effect of DKK1 overexpression on cell proliferation was tested by MTT and colony formation assays. From the cell growth curve presented in Fig. 2A, it was demonstrated that DKK1 overexpression significantly promoted proliferation of SBC-3 cells compared with the parental SBC-3 cells (*P*<0.05). Consistently, by colony formation assay, an increased number of colonies (which were also larger in diameter) were observed in SBC-3-DKK1 cells compared with parental SBC-3 cells.
parental SBC-3 cells (P<0.05; Fig. 2B and C). To conclude, these results implied that DKK1 acted as a promoter of cell proliferation in SBC-3 cells.

**Figure 3.** Migration ability of SBC-3-DKK1 and parental SBC-3 cells. Representative images of the stained migrated cells in the (A) parental SBC-3 group, (B) SBC-3-DKK1 group, (C) SBC-3 cells with recombinant human DKK1 in the bottom chamber, (D) SBC-3 cells with 50% CM and (E) SBC-3-DKK1 cells with a DKK1-neutralizing antibody in the bottom chamber. (F) Quantification of the results from the cell migration assay. Data are expressed as mean ± standard deviation. *P<0.05 compared with control group and #P<0.05 compared with SBC-3-DKK1 group. DKK1, Dickkopf1; CM, conditioned media.

**Figure 4.** Invasion ability of SBC-3-DKK1 and parental SBC-3 cells. Representative images of the stained invaded cells in the (A) parental SBC-3 group, (B) SBC-3-DKK1 group, (C) SBC-3 cells with recombinant human DKK1 in the bottom chamber, (D) SBC-3 cells with 50% CM and (E) SBC-3-DKK1 cells with a DKK1-neutralizing antibody in the bottom chamber. (F) Quantification of the results from the cell invasion assay. Data are expressed as mean ± standard deviation. *P<0.05 compared with control group and #P<0.05 compared with SBC-3-DKK1 group. DKK1, Dickkopf1; CM, conditioned medium.

**DKK1 overexpression increases migration and invasion in SBC-3 cells.** Results from the transwell assays indicated that upregulation of DKK1 significantly increased the invasive
and migratory capabilities of SBC-3 cells (Figs. 3 and 4). Furthermore, addition of recombinant DKK1 or CM from SBC-5 cells had the same effect in increasing migration and invasion of SBC-3 cells (Figs. 3 and 4). By contrast, addition of the DKK1-neutralizing antibody in the SBC-3-DKK1 cells reversed the effect of DKK1 overexpression on cell invasion and migration (Figs. 3 and 4).

Overexpression of DKK1 facilitates bone metastasis in vivo. X-ray imaging was used to investigate whether overexpression of DKK1 had an effect on in vivo metastasis. As presented in Table II, bone metastasis was observed in 3 of 5 mice in the SBC-3-DKK1 group, while no metastasis (0/5) was detected in the control SBC-3 group. Furthermore, the total number of bone metastasis lesions was counted (Table II). The results suggested that upregulation of DKK1 could enhance metastasis to bone. Representative X-ray images of skeletal metastasis are shown in Fig. 5.

Discussion

DKK1, a secreted inhibitor of the Wnt/β-catenin pathway, is a member of the human DKK family. Many of these extensively studied members have been evolutionarily conserved and include an intricate network of signaling molecules known to participate in bone diseases, Alzheimer's disease and cancer (11-15). Several reports associate DKK1 expression with skeletal lesions. DKK1 has a promoting role in the formation of bone lesions in patients with multiple myeloma (16,17), since DKK1 can prohibit osteoblastic differentiation. Consistently, elevated circulating DKK-1 levels in patients with multiple myeloma have been associated with osteolytic lesions (18,19). Furthermore, DKK1 is expressed at a higher level the MDA-MB-231-BO breast cancer cell line, which metastasizes exclusively to bone and produces larger osteolytic lesions compared to the parental MDA-MB-231 line. This advanced malignant feature is caused by inhibition in osteoblast differentiation and osteoprotegerin expression (6,20). In addition, DKK1 overexpression significantly increases the subcutaneous tumor volumes and the incidence of bone metastases of the after intracardiac Ace-1 prostate cancer cells (8). It is speculated that DKK1 may reduce the Ace-1 osteoblastic phenotype, resulting in increased phospho-46 c-Jun N-terminal kinase via the Wnt noncanonical pathway (8). A lung cancer study reported that the serum levels of DKK1 in patients with bone metastases were higher compared with NSCLC patients without bone metastasis, suggesting that DKK1 secreted by lung cancer cells may be associated with NSCLC bone metastasis (21).

A previous study from our group has demonstrated that downregulation of DKK1 in bone-metastatic SCLC cells (SBC-5) could partially inhibit cell proliferation, colony formation, migration and invasion in vitro, and bone metastases in vivo (9). In the present study, DKK1 expression was upregulated in SBC-3 cells, which have inherently low expression levels of DKK1 and no tendency to metastasize to bone tissue. The obtained results indicated that overexpression of DKK1 in SBC-3 cells was sufficient to enhance their capacity of proliferation, colony formation, migration and invasion in vitro, as well as their bone metastasis potential in vivo. In conclusion, DKK1 was demonstrated to be involved in the skeletal metastasis of SCLC cells. Furthermore, DKK1 was identified as an indispensable tumor contributor for the development of bone metastases, and therefore, it may serve as a promising target for the prevention and effective treatment of bone metastases in SCLC. Further studies will be needed in the future in order to fully elucidate the molecular mechanisms underlying the role of DKK1 on bone metastasis of lung cancer.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Natural Science Foundation of China (grant nos. 81572251 and 81402411) and the Natural Science Foundation of Shanxi, China (grant no. 2016JM8036).
Availability of data and materials

The analyzed datasets generated during the study are available from the corresponding author on reasonable request.

Authors' contributions

HP constructed stable transected cell lines and collated data. NM detected cells proliferation, colony formation and cell migration. WS was a major contributor in writing the manuscript. QZ performed the cell invasion in vitro. WC, JW and LD performed the mice experiments. NZ and ZZ were responsible for the X-ray device and evaluated osteolytic bone metastases. LL and HZ guided and reviewed the experiments. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by the Animal Experimental Ethical Inspection Committee of The Fourth Military Medical University Laboratory Animal Center (Xi’an, China).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References